Identification of BTG2, an antiproliferative p53–dependent component of the DNA damage cellular response pathway
Open accessAbstract
Cell cycle regulation is critical for maintenance of genome integrity. A prominent factor that guarantees genomic stability of cells is p53 (ref. 1). The P53 gene encodes a transcription factor that has a role as a tumour suppressor. Identification of p53-target genes should provide greater insight into the molecular mechanisms that mediate the tumour suppressor activities of p53. The rodent Pc3/Tis21 gene was initially described as an immediate early gene induced by tumour promoters and growth factors in PC12 and Swiss 3T3 cells. It is expressed in a variety of cell and tissue types and encodes a remarkably labile protein. Pc3/Tis21 has a strong sequence similarity to the human antiproliferative BTG1 gene cloned from a chromosomal translocation of a B-cell chronic lymphocytic leukaemia. This similarity led us to speculate that BTG1 and the putative human homologue of Pc3/Tis21 (named BTG2) were members of a new family of genes involved in growth control and/or differentiation. This hypothesis was recently strengthened by the identification of a new antiproliferative protein, named TOB, which shares sequence similarity with BTG1 and PC3/TIS21 (ref. 7). Here, we cloned and localized the human BTG2 gene. We show that BTG2 expression is induced through a p53-dependent mechanism and that BTG2 function may be relevant to cell cycle control and cellular response to DNA damage.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
BTG2 can induce G1/S cell cycle arrest.
“The p53 target genes BTG236, 154, 155 and GADD45A13, 156 can also induce G1/S and G2/M cell cycle arrest, respectively.”
From Census and evaluation of p53 target genes (2017) · cites this paper as [155]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321 · see citing works
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138 · see citing works
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649 · see citing works
Participation of p53 protein in the cellular response to DNA damage.
Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 3,761 · see citing works
Hartwell, L. H., & Kastan, M. B. (1994) · Science · doi:10.1126/science.7997877 · Cited by 2,523 · see citing works
Thymocyte apoptosis induced by p53-dependent and independent pathways
Clarke, A. R., Purdie, C. A., Harrison, D. J., Morris, R. G., Bird, C. C., Hooper, M. L., & Wyllie, A. H. (1993) · Nature · doi:10.1038/362849a0 · Cited by 2,271 · see citing works
Mice Lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control
Deng, C., Zhang, P., Wade Harper, J., Elledge, S. J., & Leder, P. (1995) · Cell · doi:10.1016/0092-8674(95)90039-x · Cited by 2,113 · see citing works
Definition of a consensus binding site for p53
El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., & Vogelstein, B. (1992) · Nature Genetics · doi:10.1038/ng0492-45 · Cited by 1,985 · see citing works
Vogelstein, B. (1992) · Cell · doi:10.1016/0092-8674(92)90421-8 · Cited by 1,862 · see citing works
Suppression of Human Colorectal Carcinoma Cell Growth by Wild-Type p53
Baker, S. J., Markowitz, S. D., Fearon, E. R., Willson, J. K. V., & Vogelstein, B. (1990) · Science · doi:10.1126/science.2144057 · Cited by 1,742 · see citing works
Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen
Noda, A., Ning, Y., Venable, S. F., Pereira-Smith, O. M., & Smith, J. R. (1994) · Experimental Cell Research · doi:10.1006/excr.1994.1063 · Cited by 1,351 · see citing works
Radiation-induced cell cycle arrest compromised by p21 deficiency
Brugarolas, J., Chandrasekaran, C., Gordon, J. I., Beach, D., Jacks, T., & Hannon, G. J. (1995) · Nature · doi:10.1038/377552a0 · Cited by 1,242 · see citing works
p21 is necessary for the p53-mediated G1 arrest in human cancer cells.
Waldman, T. A., Kinzler, K. W., & Vogelstein, B. (1995) · PubMed · Cited by 1,203 · see citing works
The RAD9 Gene Controls the Cell Cycle Response to DNA Damage in Saccharomyces cerevisiae
Weinert, T. A., & Hartwell, L. H. (1988) · Science · doi:10.1126/science.3291120 · Cited by 1,171 · see citing works
Agarwal, M. L., Agarwal, A., Taylor, W. R., & Stark, G. R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.18.8493 · Cited by 858 · see citing works
Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line.
Shaw, P. H., Bovey, R., Tardy, S., Sahli, R., Sordat, B., & Costa, J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4495 · Cited by 848 · see citing works
Self-citationPresence of a Potent Transcription Activating Sequence in the p53 Protein
Fields, S., & Jang, S. K. (1990) · Science · doi:10.1126/science.2144363 · Cited by 790 · see citing works
Michalovitz, D., Halevy, O., & Oren, M. (1990) · Cell · doi:10.1016/0092-8674(90)90113-s · Cited by 769 · see citing works
Identification of a p53-dependent negative response element in the bcl-2 gene.
Miyashita, T., Harigai, M., Hanada, M., & Reed, J. C. (1994) · PubMed · Cited by 746 · see citing works
Transcriptional Activation by Wild-Type but Not Transforming Mutants of the p53 Anti-Oncogene
Raycroft, L., Wu, H., & Lozano, G. (1990) · Science · doi:10.1126/science.2144364 · Cited by 620 · see citing works
Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines.
Bártek, J., Iggo, R. D., Gannon, J., & Lane, D. P. (1990) · PubMed · Cited by 603 · see citing works
Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues.
El‐Deiry, W. S., Tokino, T., Waldman, T. A., Oliner, J., Velculescu, V. E., Burrell, M., HILL, D. E., Healy, E., Rees, J. L., & Hamilton, S. R. (1995) · PubMed · Cited by 582 · see citing works
p53 modulation of TFIIH–associated nucleotide excision repair activity
Wang, X. W., Yeh, H., Schaeffer, L., Roy, R., Moncollin, V., Egly, J., Wang, Z., Friedberg, E. C., Evans, M. K., Taffe, B. G., et al. (1995) · Nature Genetics · doi:10.1038/ng0695-188 · Cited by 550 · see citing works
Abnormal structure and expression of p53 gene in human hepatocellular carcinoma.
Paillerets, B. B., Galvin, K. M., Liang, T. J., Isselbacher, K. J., Wands, J. R., & Öztürk, M. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1973 · Cited by 415 · see citing works
Evidence for a second cell cycle block at G2/M by p53.
Stewart, N., Hicks, G. G., PARASKEVAS, F., & Mowat, M. R. A. (1995) · PubMed · Cited by 300 · see citing works
BTG1, a member of a new family of antiproliferative genes.
Rouault, J.-P., Rimokh, R., Tessa, C., Paranhos‐Baccalà, G., Ffrench, M., Duret, L., Garoccio, M., Germain, D., Samarut, J., & Magaud, J. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05213.x · Cited by 299 · see citing works
Self-citationPowell, S. N., DeFrank, J. S., Connell, P., Eogan, M., Preffer, F. I., Dombkowski, D., Tang, W., & Friend, S. H. (1995) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(95)97825-l · Cited by 269 · see citing works
Deletion of genes on chromosome 1 in endocrine neoplasia
Mathew, C. G., Smith, B. A., Thorpe, K. L., Wong, Z., Royle, N. J., Jeffreys, A. J., & Ponder, B. A. J. (1987) · Nature · doi:10.1038/328524a0 · Cited by 259 · see citing works
Savatier, P., Huang, S., Székely, L., Wiman, K. G., & Samarut, J. (1994) · PubMed · Cited by 245 · see citing works
Self-citationTob, a novel protein that interacts with p185erbB2, is associated with anti-proliferative activity.
Matsuda, S., Kawamura-Tsuzuku, J., Ohsugi, M., Yoshida, M., Emi, M., Nakamura, Y., Onda, M., Yoshida, Y., Nishiyama, A., & Yamamoto, T. (1996) · PubMed · Cited by 195 · see citing works
Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene.
Casey, G., LO-HSUEH, M., Lopez, M. E., et al. (1991) · PubMed · Cited by 189 · see citing works
Bradbury, A. M., Possenti, R., Shooter, E. M., & Tirone, F. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.8.3353 · Cited by 183 · see citing works
Fletcher, B. S., Lim, R. W., Varnum, B. C., Kujubu, D. A., Koski, R. A., & Herschman, H. R. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98716-8 · Cited by 169 · see citing works
Retinoblastoma and p 53 tumor suppressor genes in human hepatoma cell lines
Puisieux, A., Galvin, K. M., Troalen, F., Paillerets, B. B., Marçais, C., Galun, E., Ponchel, F., Yakıcıer, C., Ji, J., & Öztürk, M. (1993) · The FASEB Journal · doi:10.1096/fasebj.7.14.8224613 · Cited by 125 · see citing works
Self-citationPowell, S. N., DeFrank, J. S., Connell, P., Eogan, M., Preffer, F. I., Dombkowski, D., Tang, W., & Friend, S. H. (1995) · PubMed · Cited by 121 · see citing works
Effects of Drugs on the Cell Nucleus
Fox, B. W. (1980) · British Journal of Cancer · doi:10.1038/bjc.1980.348 · Cited by 118 · see citing works
Loss of heterozygosity on chromosome 1q in human breast cancer.
Chen, L. C., Dollbaum, C. M., & Smith, H. S. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.18.7204 · Cited by 118 · see citing works
Aloni-Grinstein, R., Schwartz, D., & Rotter, V. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07125.x · Cited by 105 · see citing works
Chérif, D., Julier, C., Delattre, O., et al. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.17.6639 · Cited by 103 · see citing works
A Gene Involved in Control of Human Cellular Senescence on Human Chromosome 1q
Hensler, P. J., Annab, L. A., Barrett, J. C., & Pereira‐Smith, O. M. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.4.2291 · Cited by 95 · see citing works
A functional screen for germ line p53 mutations based on transcriptional activation.
Frébourg, T., Barbier, N., Kassel, J., Ng, Y. S., Beer‐Romero, P., & Friend, S. H. (1992) · PubMed · Cited by 64 · see citing works
Paraskrva, C., Finerty, S., & Powell, S. (1988) · International Journal of Cancer · doi:10.1002/ijc.2910410624 · Cited by 50 · see citing works
Introduction of wild-type p53 in a human ovarian cancer cell line not expressing endogenous p53
Vikhanskaya, F., Erba, E., D’Incalci, M., & Broggini, M. (1994) · Nucleic Acids Research · doi:10.1093/nar/22.6.1012 · Cited by 49 · see citing works
Takahashi, K., Sumimoto, H., Suzuki, K., & Ono, T. (1993) · Molecular Carcinogenesis · doi:10.1002/mc.2940080112 · Cited by 39 · see citing works
Varnum, B. C., Reddy, S. T., Koski, R. A., & Herschman, H. R. (1994) · Journal of Cellular Physiology · doi:10.1002/jcp.1041580125 · Cited by 39 · see citing works
Effects of drugs on the cell nucleus
Busch, H., Crooke, S. T., & Daskal, Y. (1979) · Medical Entomology and Zoology · Cited by 27 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
The multiple mechanisms that regulate p53 activity and cell fate
Hafner, A., Bulyk, M. L., Jambhekar, A., & Lahav, G. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0110-x · Cited by 1,129 · see citing works
Census and evaluation of p53 target genes
Fischer, M. (2017) · Oncogene · doi:10.1038/onc.2016.502 · Cited by 971 · see citing works
Guardavaccaro, D., Corrente, G., Covone, F., Micheli, L., D'Agnano, I., Starace, G., Caruso, M., & Tirone, F. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.5.1797-1815.2000 · Cited by 230 · see citing works
The transcription factor p53: Not a repressor, solely an activator.
Fischer, M., Steiner, L., & Engeland, K. (2014) · Cell Cycle · doi:10.4161/15384101.2014.949083 · Cited by 153 · see citing works
Schlereth, K., Heyl, C., Krampitz, A.-M., Mernberger, M., Finkernagel, F., Scharfe, M., Jarek, M., Leich, E., Rosenwald, A., & Stiewe, T. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003726 · Cited by 87 · see citing works
Duriez, C., Falette, N., Audoynaud, C., Moyret-Lalle, C., Bensaad, K., Courtois, S., Wang, Q., Soussi, T., & Puisieux, A. (2002) · Gene · doi:10.1016/s0378-1119(01)00825-3 · Cited by 73 · see citing works
Self-citationA genomics approach identifies senescence‐specific gene expression regulation
Lackner, D. H., Hayashi, M. T., Cesare, A. J., & Karlseder, J. (2014) · Aging Cell · doi:10.1111/acel.12234 · Cited by 47 · see citing works
“We also identified genes with established roles in senescence (p21, p16) or with antiproliferative properties such as WNT16 (Binet et al., 2009), or BTG2 (Rouault et al., 1996).”
BackgroundTirone, F., Farioli-Vecchioli, S., Micheli, L., Ceccarelli, M., & Leonardi, L. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00059 · Cited by 32 · see citing works
Sokolov, M., & Neumann, R. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15010588 · Cited by 23 · see citing works
Functional investigations of p53 acetylation enabled by heterobifunctional molecules
Chen, L.-Y., Singha Roy, S. J., Jadhav, A. M., Wang, W. W., Chen, P.-H., Bishop, T., Erb, M. A., & Parker, C. G. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.4c00438 · Cited by 18 · see citing works
- Authors
- Rouault, J.-P., Falette, N., Guéhenneux, F., Guillot, C., Rimokh, R., Wang, Q., Berthet, C., Moyret-Lalle, C., Savatier, P., Pain, B., Shaw, P., Berger, R., Samarut, J., Magaud, J.-P., Ozturk, M., Samarut, C., & Puisieux, A.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Centre Léon Bérard (FR)
- École Normale Supérieure de Lyon (FR)
- Inserm (FR)
- ORCID
- Venue
- Nature Genetics
- Published
- 1996-12
- Volume
- 14
- Issue
- 4
- Pages
- 482-486
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2028468783
- Cited by
- 434
- References
- 46
- Citations by year
- 2026: 8 · 2025: 10 · 2024: 18 · 2023: 9 · 2022: 19 · 2021: 9 · 2020: 12 · 2019: 8 · 2018: 15 · 2017: 12 · 2016: 8 · 2015: 20 · 2014: 25 · 2013: 23 · 2012: 21
- FWCI
- 3.90
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Bilkent University Institutional Repository (Bilkent University) (submittedVersion)
- HAL (submittedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- BTG2, BTG1, p53, p53 target genes, DNA damage response, cell cycle regulation, tumour suppressor, gene cloning, genome stability
- MeSH terms
- Amino Acid Sequence, Animals, Cell Cycle, Cell Division, Cell Line, Chromosome Mapping, Chromosomes, Human, Pair 1, Cloning, Molecular, DNA Damage, Gene Expression Regulation, Humans, Hybrid Cells, Molecular Sequence Data, Neoplasm Proteins, Proteins, Genes, Tumor Suppressor, Tumor Suppressor Protein p53, 3T3 Cells, Sequence Homology, Amino Acid, Immediate-Early Proteins, Tumor Suppressor Proteins, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
